Aqr Capital Management LLC Editas Medicine, Inc. Transaction History

Aqr Capital Management LLC

  • $71.5 Billion
  • Q3 2024

A detailed history of Aqr Capital Management LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 376,197 shares of EDIT stock, worth $906,634. This represents 0.0% of its overall portfolio holdings.

Number of Shares
376,197
Previous 45,890 719.78%
Holding current value
$906,634
Previous $214,000 499.07%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$3.39 - $5.96 $1.12 Million - $1.97 Million
330,307 Added 719.78%
376,197 $1.28 Million
Q2 2024

Aug 14, 2024
BUY
$4.67 - $7.28 $115,619 - $180,238
24,758 Added 117.16%
45,890 $214,000
Q1 2024

May 15, 2024
BUY
$7.03 - $11.07 $148,557 - $233,931
21,132 New
21,132 $156,000
Q3 2023

Nov 14, 2023
BUY
$6.92 - $9.31 $63,373 - $85,260
9,158 Added 32.97%
36,933 $288,000
Q2 2023

Aug 14, 2023
SELL
$6.36 - $11.47 $180,833 - $326,126
-28,433 Reduced 50.59%
27,775 $228,000
Q1 2023

May 15, 2023
BUY
$7.03 - $11.53 $164,825 - $270,332
23,446 Added 71.56%
56,208 $407,000
Q4 2022

Feb 14, 2023
BUY
$8.32 - $13.21 $272,579 - $432,786
32,762 New
32,762 $290,000
Q2 2022

Aug 15, 2022
SELL
$9.99 - $21.35 $488,501 - $1.04 Million
-48,899 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$14.08 - $27.63 $489,603 - $960,777
34,773 Added 246.16%
48,899 $930,000
Q4 2021

Feb 14, 2022
SELL
$26.55 - $40.57 $193,522 - $295,714
-7,289 Reduced 34.04%
14,126 $375,000
Q3 2021

Nov 15, 2021
BUY
$39.27 - $72.94 $203,261 - $377,537
5,176 Added 31.87%
21,415 $880,000
Q2 2021

Aug 16, 2021
SELL
$31.29 - $56.64 $223,128 - $403,899
-7,131 Reduced 30.51%
16,239 $920,000
Q1 2021

May 17, 2021
BUY
$39.71 - $90.58 $277,493 - $632,973
6,988 Added 42.66%
23,370 $982,000
Q4 2020

Feb 16, 2021
SELL
$27.07 - $84.35 $215,152 - $670,413
-7,948 Reduced 32.67%
16,382 $1.15 Million
Q3 2020

Nov 16, 2020
SELL
$28.06 - $37.16 $318,817 - $422,211
-11,362 Reduced 31.83%
24,330 $683,000
Q2 2020

Aug 17, 2020
SELL
$18.5 - $34.34 $77,589 - $144,021
-4,194 Reduced 10.51%
35,692 $1.06 Million
Q1 2020

May 15, 2020
BUY
$14.88 - $32.78 $593,503 - $1.31 Million
39,886 New
39,886 $791,000
Q4 2018

Feb 14, 2019
SELL
$18.19 - $31.79 $364,054 - $636,245
-20,014 Closed
0 $0
Q3 2018

Nov 15, 2018
BUY
$27.65 - $38.39 $116,710 - $162,044
4,221 Added 26.73%
20,014 $637,000
Q1 2018

May 15, 2018
BUY
$29.84 - $44.08 $233,110 - $344,352
7,812 Added 97.88%
15,793 $524,000
Q4 2017

Feb 14, 2018
BUY
$21.89 - $31.34 $174,704 - $250,124
7,981
7,981 $245,000

Others Institutions Holding EDIT

# of Institutions
247
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $166M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email